JP2018513216A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513216A5 JP2018513216A5 JP2018505578A JP2018505578A JP2018513216A5 JP 2018513216 A5 JP2018513216 A5 JP 2018513216A5 JP 2018505578 A JP2018505578 A JP 2018505578A JP 2018505578 A JP2018505578 A JP 2018505578A JP 2018513216 A5 JP2018513216 A5 JP 2018513216A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- medicine
- antigen receptor
- cells
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562147793P | 2015-04-15 | 2015-04-15 | |
| US62/147,793 | 2015-04-15 | ||
| PCT/US2016/027582 WO2016168493A1 (en) | 2015-04-15 | 2016-04-14 | Hepatic arterial infusion of car-t cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018513216A JP2018513216A (ja) | 2018-05-24 |
| JP2018513216A5 true JP2018513216A5 (enExample) | 2019-05-23 |
Family
ID=57126310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505578A Pending JP2018513216A (ja) | 2015-04-15 | 2016-04-14 | Ｃａｒ−ｔ細胞の肝動脈注入 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10471098B2 (enExample) |
| EP (1) | EP3283083A4 (enExample) |
| JP (1) | JP2018513216A (enExample) |
| KR (1) | KR20180021364A (enExample) |
| CN (1) | CN108135937A (enExample) |
| AR (1) | AR104296A1 (enExample) |
| AU (1) | AU2016248090A1 (enExample) |
| CA (1) | CA2982603A1 (enExample) |
| HK (1) | HK1251179A1 (enExample) |
| IL (1) | IL255005A0 (enExample) |
| MX (1) | MX2017013247A (enExample) |
| TW (1) | TWI719019B (enExample) |
| WO (1) | WO2016168493A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6979882B2 (ja) | 2015-06-24 | 2021-12-15 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | 脳組織の治療のための組織破砕療法システムおよび方法 |
| CN107056952A (zh) * | 2017-05-10 | 2017-08-18 | 常州市第人民医院 | Cea.car‑t及其制备与应用 |
| WO2019030757A1 (en) * | 2017-08-09 | 2019-02-14 | Ctg Pharma Ltd. | CHIMERIC ANTIGEN RECEPTOR FOR HER2 / NEU AND LYMPHOCYTES T THE EXPRESSANT |
| EP3704156A1 (en) | 2017-11-03 | 2020-09-09 | Sorrento Therapeutics, Inc. | Cd38-directed chimeric antigen receptor constructs |
| SG11202003956TA (en) * | 2017-11-30 | 2020-06-29 | Singapore Health Serv Pte Ltd | A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient |
| CN112105649B (zh) | 2018-03-09 | 2025-09-05 | 索伦托药业有限公司 | 二聚体抗原受体(dar) |
| JP2021532116A (ja) * | 2018-07-23 | 2021-11-25 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | 同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用 |
| IL280329B2 (en) * | 2018-08-02 | 2024-09-01 | Kite Pharma Inc | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
| CN112384231A (zh) * | 2018-08-26 | 2021-02-19 | 奥伊斯细胞生物技术公司 | 用于治疗胶质母细胞瘤的方法 |
| AU2019337603B2 (en) * | 2018-09-13 | 2026-03-05 | Nkarta, Inc. | Natural killer cell compositions and immunotherapy methods for treating tumors |
| CN113286552B (zh) | 2018-11-28 | 2025-05-02 | 希斯托索尼克斯公司 | 组织摧毁术系统及方法 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| EP3799881A1 (en) | 2019-10-04 | 2021-04-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Single domain antibodies specifically binding globo - series glycans |
| BR112022009181A2 (pt) * | 2019-11-25 | 2022-07-26 | Univ Kyoto | Sistema para prover um produto de célula t, métodos para produzir um produto de célula t, para construir um banco celular e uma coleção de produto de célula t e para prover um produto de célula t, banco celular, coleções de banco celular e de produto de célula t, e, produto de célula t |
| JP2023513012A (ja) * | 2020-01-28 | 2023-03-30 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | ヒストトリプシー免疫感作のためのシステムおよび方法 |
| JP2023530477A (ja) | 2020-06-18 | 2023-07-18 | ヒストソニックス，インコーポレーテッド | 組織破砕音響／患者結合システムおよび方法 |
| CN116782843A (zh) | 2020-08-27 | 2023-09-19 | 密歇根大学董事会 | 用于组织摧毁术的具有发射-接收能力的超声换能器 |
| EP4217064A4 (en) * | 2020-09-22 | 2024-08-07 | TriSalus Life Sciences, Inc. | CANCER THERAPY WITH TOLL-LIKE RECEPTOR AGONISTS |
| CN116685330A (zh) * | 2020-09-22 | 2023-09-01 | 特萨乐斯生命科学公司 | 使用toll样受体激动剂的癌症疗法 |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| CA3204922A1 (en) * | 2021-02-09 | 2022-08-18 | Ming-Tain Lai | Globo series antigens-binding chimeric antigen receptors and uses thereof |
| US20240149078A1 (en) | 2022-10-28 | 2024-05-09 | Histosonics, Inc. | Histotripsy systems and methods |
| KR20260003742A (ko) | 2023-04-20 | 2026-01-07 | 히스토소닉스, 인크. | 치료 계획 및 요법을 위한 사용자 인터페이스들 및 작업 흐름들을 포함하는 히스토트립시 시스템들 및 연관된 방법들 |
| WO2025144964A2 (en) * | 2023-12-29 | 2025-07-03 | AffyImmune Therapeutics Inc. | Novel car constructs and methods of treatment |
| WO2026052782A1 (en) | 2024-09-06 | 2026-03-12 | Tacalyx Gmbh | Anti-globo h antibodies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874540A (en) * | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| US20020165360A1 (en) * | 2000-11-30 | 2002-11-07 | Junghans Richard P. | Chimeric effector cell receptors against carcinoembryonic antigen |
| WO2010085660A2 (en) | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| RU2688185C2 (ru) * | 2011-03-23 | 2019-05-21 | Фред Хатчинсон Кэнсер Рисерч Сентер | Способ и композиции для клеточной иммунотерапии |
| CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| CN112458057A (zh) | 2012-10-02 | 2021-03-09 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| EP2961831B1 (en) | 2013-02-26 | 2020-06-10 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
-
2016
- 2016-04-14 KR KR1020177033070A patent/KR20180021364A/ko not_active Withdrawn
- 2016-04-14 AU AU2016248090A patent/AU2016248090A1/en not_active Abandoned
- 2016-04-14 CN CN201680035380.XA patent/CN108135937A/zh active Pending
- 2016-04-14 HK HK18110746.6A patent/HK1251179A1/zh unknown
- 2016-04-14 TW TW105111666A patent/TWI719019B/zh not_active IP Right Cessation
- 2016-04-14 CA CA2982603A patent/CA2982603A1/en not_active Abandoned
- 2016-04-14 MX MX2017013247A patent/MX2017013247A/es unknown
- 2016-04-14 JP JP2018505578A patent/JP2018513216A/ja active Pending
- 2016-04-14 WO PCT/US2016/027582 patent/WO2016168493A1/en not_active Ceased
- 2016-04-14 EP EP16780765.0A patent/EP3283083A4/en not_active Withdrawn
- 2016-04-14 US US15/099,370 patent/US10471098B2/en not_active Expired - Fee Related
- 2016-04-15 AR ARP160101045A patent/AR104296A1/es unknown
-
2017
- 2017-10-15 IL IL255005A patent/IL255005A0/en unknown
-
2019
- 2019-10-09 US US16/597,798 patent/US20200138863A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018513216A5 (enExample) | ||
| Alnefaie et al. | Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions | |
| Pento | Monoclonal antibodies for the treatment of cancer | |
| CN113286879B (zh) | 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子 | |
| Harrer et al. | RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma | |
| Tai et al. | B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma | |
| Whiteside et al. | Emerging opportunities and challenges in cancer immunotherapy | |
| JP2017507917A5 (enExample) | ||
| Ma et al. | Advanced generation anti‐prostate specific membrane antigen designer T Cells for prostate cancer immunotherapy | |
| EP2990416B1 (en) | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders | |
| JP2017509342A5 (enExample) | ||
| AU2025205213A1 (en) | Chimeric antigen receptor T cells targeting the tumor microenvironment | |
| Alcaide et al. | Myocardial inflammation in heart failure with reduced and preserved ejection fraction | |
| JP2017537622A5 (enExample) | ||
| EP3714941A1 (en) | Mage-a4 tcrs | |
| JP2018509163A5 (enExample) | ||
| JP2017537627A5 (enExample) | ||
| CN116970630A (zh) | 用于细胞治疗的组成型活性细胞因子受体 | |
| JP2020517658A5 (enExample) | ||
| JP2017538401A5 (enExample) | ||
| RU2017102769A (ru) | EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА | |
| JP2017507936A5 (enExample) | ||
| JP2020510704A5 (enExample) | ||
| JP2016520074A5 (enExample) | ||
| JP2016519933A5 (enExample) |